P3-279: SERUM AND CSF BIOMARKERS IN STROKE-FREE PATIENTS ARE ASSOCIATED WITH VASCULAR RISK FACTORS AND COGNITIVE PERFORMANCE: A NON-TARGETED METABOLOMICS STUDY
Sisi Peng,Ying Shen,Junjian Zhang
DOI: https://doi.org/10.1016/j.jalz.2019.06.3310
2019-01-01
Alzheimer s & Dementia
Abstract:Aggregation of vascular risk factors (VRFs) can aggravate cognitive impairment in stroke-free patients. Metabolites in serum and cerebrospinal fluid (CSF) also irreversibly lead to deterioration. This study evaluates the small molecule metabolites (＜1000Da) in serum and CSF in patients with different degrees of cerebrovascular burden, and investigates the correlation between metabolism and cognitive performance associated with VRFs. Subjects were divided into low-risk group (10-year stroke risk ≤ 5%), middle-risk group (10-year stroke risk ＞5% and ＜15%) and high risk group (10 years stroke risk ≥ 15%) according to the Framingham stroke risk profile (FSRP) score, which was used to quantify VRFs. Montreal Cognitive Assessment (MoCA), Rey auditory verbal learning test (RAVLT), Digital sign substitution test (DSST), Digit span test (DST), Verbal fluency test (VFT) were applied to evaluate the cognitive function of participants. We semi-quantitatively quantified the small molecules using the liquid chromatography-mass spectrometry (LCMS). The correlation between small molecules and cognitive function along with VRFs was investigated, aiming at discovering the key small molecules and even metabolic pathways. As the FSRP scores increased, the cognitive performances of subjects decreased, specifically on the tasks of immediate memory, delayed recall, executive function. 7 metabolites (2-Aminobutyric acid, Asp Asp Ser, Asp Thr Arg, Ile Cys Arg, 1-methyluric acid, 3-tert-Butyladipic acid, 5α-Dihydrotestosterone glucuronide) in serum, 3 metabolites (Asp His, 13-HOTrE(r), 2,5-di-tert-Butylhydroquinone) in CSF were significantly increased, and 1 metabolite (Arachidonoyl PAF C-16) in serum was significantly decreased in stroke-free patients with heavier VRFs burden. Among these metabolites, 1-methyluric acid, 3-tert-Butyladipic acid, Ile Cys Arg, 13-HOTrE(r), 2,5-di-tert-Butylhydroquinone and Asp His were found associated with poor cognitive performances. Arachidonoyl PAF C-16 was found associated with better cognitive performances. Caffeine metabolism and TCA cycle were identified as key pathways. 1-methyluric acid, 3-tert-Butyladipic acid, Arachidonoyl PAF C-16, Ile Cys Arg in serum, and 13-HOTrE(r), 2,5-di-tert-Butylhydroquinone, Asp His in CSF were identified as potential biomarkers of VCI at early stage. Caffeine metabolism and TCA cycle may play an important role in the pathophysiology of VRFs-associated cognitive impairment.